Iron supplementation in a large Swiss Cohort of Inflammatory Bowel Disease patients demonstrates a shift form oral to intravenous therapy over time

Détails

ID Serval
serval:BIB_C01D45C5F4B9
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Titre
Iron supplementation in a large Swiss Cohort of Inflammatory Bowel Disease patients demonstrates a shift form oral to intravenous therapy over time
Titre de la conférence
80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin
Auteur(s)
Vavricka S., Achermann R., Rogler G., Schwenkglenks M., Schoepfer A.
Adresse
Basel, Schweiz, 23.-25. Mai 2012
ISBN
1424-4985
ISSN-L
1424-4977
Statut éditorial
Publié
Date de publication
2012
Volume
12
Série
Swiss Medical Forum = Forum Médical Suisse
Pages
S52
Langue
anglais
Résumé
Background and Aims: The 2007 European Crohn's and Colitis
Organization guidelines on anemia in inflammatory bowel disease (IBD)
favour intravenous (iv) over oral (po) iron supplementation due to better
effectiveness and tolerance. We aimed to determine the percentage of
IBD patients under iron supplementation therapy and the dynamics of
prescription habits (iv versus po) over time.
Methods: Helsana, a leading Swiss health insurance company
provides coverage for approximately 18% of the Swiss population,
corresponding to about 1.2 million enrollees. Patients with Crohn's
disease (CD) and ulcerative colitis (UC) were analyzed from the
anonymised Helsana database.
Results: In total, 629 CD (61% female) and 398 UC (57% female)
patients were identified, mean observation time was 31.8 months for CD
and 31.0 months for UC patients. Of the entire study population, 27.1%
were prescribed iron (21.1% in males and 31.1% in females). Patients
treated with IBD-specific drugs (steroids, immunomodulators, anti-TNF
agents) were more frequently treated with iron compared to patients
without any medication (35.0% vs. 20.9%, OR 1.91, 95%-CI 1.41-2.61).
The prescription of iv iron increased from 2006/2007 (48.8% of all
patients receiving any iron priscription) to 65.2% in 2008/2009 by a
factor of 1.89.
Conclusions: One third of the IBD population was treated with iron
supplementation. A gradual shift from oral to iv iron was observed over
time. This switch in prescription habits goes along with the
implementation of the ECCO consensus guidelines on anemia in IBD.
Création de la notice
14/02/2013 18:05
Dernière modification de la notice
03/03/2018 21:05
Données d'usage